Our Approach

You are here

WE ESTABLISH AND PROSECUTE DRUG DISCOVERY ALLIANCES

A Model That Works

We bring together the best minds in basic and clinical cancer research, the rigour and drive of pharmaceutical and biotech companies, and our in-house drug discovery and alliance management capabilities to deliver breakthrough medicines for cancer patients. The themed approach drives strong partner engagement, teamwork across academia and industry, high quality target selection and efficiency in drug discovery project prosecution. We have pioneered, developed and refined the model in recent years, establishing successful alliances with AstraZeneca, Teva Pharmaceuticals, Forma Therapeutics, Merck KGaA, Artios Pharma, and LifeArc (formerly MRCT).

It is a time of exciting progress in the understanding of cancer and of great progress in the development of new therapies however, unmet need remains high across many cancer types. The incentive has never been greater to bridge the gap between cutting edge academic research and organisations with the development capabilities to rapidly bring new agents to patients. At CRUK-TDL our approach is fully aligned to making Cancer Research UK’s ambition to beat cancer sooner a reality.

The goal of any of our alliances is to deliver a portfolio of projects within an area of cancer biology where there is compelling rationale for clinical relevance and patient selection. The themed approach allows clear delineation of alliance scope, focus for interaction with the academic community and the efficient triage and prosecution of multiple drug discovery targets.

This site uses cookies. Click here to find out more and how to refuse cookies.

Cancer Research UK is a registered charity in England and Wales (1089464), Scotland (SC041666) and the Isle of Man (1103). A company limited by guarantee. Registered company in England and Wales (4325234) and the Isle of Man (5713F). Registered address: Angel Building, 407 St John Street, London EC1V 4AD.